MONTREAL — Spiriva Respimat, as an add-on to inhaled corticosteroids or long-acting beta2 agonists, reduced the risk for severe asthma exacerbation in patients across severities of symptomatic asthma ...
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved ...
Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
This approval was based on efficacy and safety data from the Phase 2 and Phase 3 UniTinA-asthma clinical development program. The Food and Drug Administration (FDA) has approved Spiriva Respimat ...
The US Food and Drug Administration (FDA) has approved the long-acting beta-agonist, olodaterol (Striverdi Respimat, Boehringer Ingelheim), for long-term, once-daily maintenance treatment of airflow ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback